Fig 1: Expressions of the receptor for advanced glycation end products (RAGE) in the lung sections and bronchoalveolar lavage fluid (BALF) of ovalbumin (OVA)-challenged mice. Mice were treated or not with 0.5% methylglyoxal (MGO) for 12 weeks in the drinking water alone or combined with metformin (MET). Panels (A,B) show, respectively, representative images and percent quantification (% marked area) of RAGE by immunohistochemistry (IHC; brown staining) of the peribronchiolar regions (bar = 200 μm, 200× objective). Panel (C) shows the RAGE expression by RT-PCR in the lung homogenates, and panel (D) shows the levels in BALF. Data are expressed as mean ± SEM for (n = 7–8). * p < 0.05 compared with respective vehicle groups. # p< 0.05 compared with the MGO + OVA in vehicle groups.
Fig 2: Levels of total AGEs (A), methylglyoxal-derived hydroimidazolone (MG-H1) (B), and RAGE (C) in bladders of female ob/ob mice treated with TPP488 (10 mg/kg) or receiving vehicle (0.02% DMSO in PBS) in drinking water for 15 days. Total AGEs in panel (A) consist of N-epsilon-(carboxymethyl) lysine (CML), glyoxal-derived lysine dimer (GOLD), N-epsilon-(1-carboxyethyl) lysine (CEL), methylglyoxal-derived lysine dimer (MOLD), 3-deoxyglucosone-derived lysine dimer (DOLD), and 3-deoxyglucosone (3-DG). Data are expressed as mean ± SEM (n = 7–15 animals in each group). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the wild-type (WT) group (one-way ANOVA followed by Dunnet’s comparisons test); # p < 0.05 compared with the untreated ob/ob group (one-way ANOVA followed by Bonferroni’s multiple comparisons test).
Supplier Page from Abcam for Mouse RAGE ELISA Kit